European journal of rheumatology and inflammation最新文献_第10页

Double-blind study of tenoxicam 20 mg versus piroxicam 20 mg in rheumatoid arthritis. 替诺昔康20mg与吡罗西康20mg治疗类风湿关节炎的双盲研究。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

H Havranek

引用次数: 0

A long-term, double-blind, comparative study of tenoxicam (Ro 12-0068) and piroxicam in gonarthrosis and coxarthrosis. 一项长期、双盲、替诺昔康(Ro 12-0068)和吡罗西康治疗踝关节和关节关节病的比较研究。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

J J Orozco-Alcalá, E F Barrera-Tenorio

引用次数: 0

Double-blind parallel study of tenoxicam (20 mg vs. 40 mg) in extra-articular inflammation. 替诺昔康(20mg vs 40mg)治疗关节外炎症的双盲平行研究。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

L Tuso, F Jeunet, G Kunovits, M Pasquier

引用次数: 0

Non-steroidal anti-inflammatory drugs and the classical arthritides: focus on five-years of piroxicam experience. 非甾体抗炎药和经典关节炎:关注吡罗昔康5年的经验。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

A Calin

{"title":"Non-steroidal anti-inflammatory drugs and the classical arthritides: focus on five-years of piroxicam experience.","authors":"A Calin","doi":"","DOIUrl":"","url":null,"abstract":"In recent years, we have seen immense progress in our understanding of rheumatic diseases. As we learn more about the pathogenetic mechanisms of disease, we can begin to classify the disorders more rationally. However, treatment lags behind understanding; we still direct our attention toward inflammation in a non-specific manner. At the beginning of the century, aspirin became a widely used treatment for all forms of arthritis. By the early 1960s, phenylbutazone and then indomethacin were introduced, and later, ibuprofen, naproxen, sulindac, and a variety of other agents had become available. Within the last five years two new agents were introduced that were characterised by a once-a-day regimen. One piroxicam - worked by attacking the cyclooxygenase pathway. The other--benoxaprofen--inhibited both the cyclooxygenase and lipoxygenase pathways, but had to be withdrawn because it was toxic. Since piroxicam was introduced in 1980, eight nonsteroidal anti-inflammatory drugs (NSAIDs) have been withdrawn from the market in the United Kingdom. By contrast, piroxicam is now available in over 90 countries and has been used safely and successfully in millions of people of different ages and in different clinical settings. Short-term open studies, controlled studies, and more recent long-term studies lasting over periods of more than three years give further evidence of effectiveness and tolerance.","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"8 1","pages":"24-30"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14431873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Piroxicam in acute musculoskeletal disorders and sport injuries. 吡罗西康在急性肌肉骨骼疾病和运动损伤中的应用。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

L P Heere

引用次数: 0

Evaluation of tenoxicam in rheumatology--clinical trial results in Argentina and Brazil. 替诺昔康在风湿病学中的评价——阿根廷和巴西的临床试验结果。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

C A Barclay, C A Traballi

{"title":"Evaluation of tenoxicam in rheumatology--clinical trial results in Argentina and Brazil.","authors":"C A Barclay, C A Traballi","doi":"","DOIUrl":"","url":null,"abstract":"The therapeutic activity of tenoxicam, a thienothiazine derivative with analgesic and anti-inflammatory properties, has been studied by 15 investigators in Argentina and Brazil. Twenty-nine clinical trials were performed in a total of 747 patients suffering from rheumatoid arthritis (270), cox- and gonarthrosis (190), extra-articular inflammation (250) and acute gout (37). Out of the patients studied, 507 received tenoxicam and 240 were given comparative preparations. In 76% of the patients 20 mg tenoxicam was given as a single daily dose. In most patients duration of treatment was either six weeks or six months. Therapeutic results were evaluated according to the evolution of pain in various conditions as well as that of the articular, clinical and functional status. Once treatment was concluded a global evaluation of efficacy and tolerance was performed. The statistical analysis showed a significant improvement, in comparison to baseline, in all parameters considered under the different conditions. Double-blind studies showed no significant statistical differences between tenoxicam and the comparative preparations. Tolerance to tenoxicam was considered excellent, granting that some patients referred to adverse effects of the gastrointestinal type, such as epigastric discomfort, pyrosis and flatulence of moderate intensity. Tenoxicam is a new non-steroidal anti-inflammatory compound which is well tolerated and has excellent activity in the treatment of diverse rheumatoid conditions.","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"9 2","pages":"26-50"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14455759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tenoxicam in the treatment of extra-articular inflammatory processes. 替诺昔康治疗关节外炎症。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

S C de Carvalho, P Fiszman, J B Perpétuo, R Lederman, T Yoneda, A Sidi

引用次数: 0

Rheumatology--past, present, and future. 风湿病学——过去、现在和未来。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

M Schattenkirchner

{"title":"Rheumatology--past, present, and future.","authors":"M Schattenkirchner","doi":"","DOIUrl":"","url":null,"abstract":"From ancient times until the middle of the last century--the beginning of the modern scientific era--the description, classification, and study of rheumatologic phenomena played an important role in medicine. There are numerous examples in the literature, beginning with Hippocrates' observations on gout through the discoveries of Sydenham and Heberden. The detection of uric acid as \"materia peccans\" in gouty arthritis and the differentiation of the chronic arthritides by Garrod in 1853 marked the start of research into the aetiology and pathogenesis of rheumatic diseases. After Garrod's discovery, observation and description of rheumatic diseases lagged, and the only treatment in common usage was symptomatic and left to spas. In the last few decades, interest in the classification of rheumatic disease revived, and the union of clinical rheumatology with basic research provided the basis of a period of rapid progress in the knowledge of pathogenesis and in the development of symptomatic therapies, including non-steroidal anti-inflammatory drugs (NSAIDs). Two major therapeutic goals mark the future of rheumatology: the search for optimum treatment to halt the manifestations of rheumatic diseases and the search for the aetiology, which would lead eventually to prevention and cure.","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"8 1","pages":"31-7"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14621299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The International League Against Rheumatism. 国际抗风湿病联盟。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

E P Engleman

引用次数: 0

Tenoxicam or diclofenac in the treatment of gonarthrosis. 替诺昔康或双氯芬酸治疗关节病。

European journal of rheumatology and inflammation Pub Date : 1987-01-01

W H Chahade, G C Marques

引用次数: 0